Mirae Asset Global Investments Co. Ltd. Sells 22,532 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Mirae Asset Global Investments Co. Ltd. cut its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 37.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 38,187 shares of the biopharmaceutical company's stock after selling 22,532 shares during the period. Mirae Asset Global Investments Co. Ltd.'s holdings in Alnylam Pharmaceuticals were worth $7,340,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of ALNY. Quent Capital LLC raised its holdings in shares of Alnylam Pharmaceuticals by 246.0% during the fourth quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company's stock worth $33,000 after acquiring an additional 123 shares during the period. KB Financial Partners LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth $35,000. Anchor Investment Management LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $38,000. First Capital Advisors Group LLC. acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth $80,000. Finally, 1832 Asset Management L.P. acquired a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth $88,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. JPMorgan Chase & Co. raised their price objective on shares of Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the stock a "neutral" rating in a report on Thursday, February 1st. Citigroup decreased their target price on shares of Alnylam Pharmaceuticals from $237.00 to $227.00 and set a "buy" rating for the company in a research report on Friday, February 16th. The Goldman Sachs Group downgraded shares of Alnylam Pharmaceuticals from a "buy" rating to a "neutral" rating and decreased their target price for the company from $230.00 to $173.00 in a research report on Friday, February 16th. Morgan Stanley decreased their target price on shares of Alnylam Pharmaceuticals from $184.00 to $176.00 and set an "equal weight" rating for the company in a research report on Tuesday, February 13th. Finally, Wells Fargo & Company decreased their target price on shares of Alnylam Pharmaceuticals from $171.00 to $161.00 and set an "equal weight" rating for the company in a research report on Friday, February 16th. Eight equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, Alnylam Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $216.12.

Alnylam Pharmaceuticals Stock Down 2.4 %

Shares of NASDAQ:ALNY traded down $3.59 during midday trading on Friday, hitting $148.50. The stock had a trading volume of 428,052 shares, compared to its average volume of 538,883. The company's 50-day moving average price is $153.99 and its 200-day moving average price is $167.73. The company has a market capitalization of $18.70 billion, a P/E ratio of -41.71 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $143.52 and a fifty-two week high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) EPS for the quarter, beating the consensus estimate of ($1.20) by $0.10. The firm had revenue of $439.72 million during the quarter, compared to analyst estimates of $439.38 million. Alnylam Pharmaceuticals's quarterly revenue was up 31.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.68) earnings per share. Research analysts expect that Alnylam Pharmaceuticals, Inc. will post -4.54 EPS for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.